ArticleACS applied nano materials2025
Copper-Silver Nanoparticle/Lipase Nanobiohybrids for Enhanced Activity Against Viral Pathogens.
Article in ACS applied nano materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of sustainable, low-toxicity materials that are effective against a wide range of microorganisms is crucial in addressing emerging infectious diseases. The recent spread of monkeypox virus (MPXV), respiratory pathogens such as rhinoviruses or seasonal coronaviruses, and animal pathogens such as porcine reproductive and respiratory syndrome virus (PRRSV) highlights the urgent need for innovative solutions in both human and animal health. In this study, we designed a bimetallic nanobiohybrid material, NanoCuAg, composed of a lipase and in situ-synthesized copper and silver nanoparticles, with a low silver-to-copper ratio, through a simple and sustainable synthetic process. The nanobiomaterial, featuring a supramolecular flower structure containing ∼4 nm average diameter nanoparticles, contains 32% copper and 3% silver, mainly in the Cu-(II) and Ag-(I) oxidation states. Despite its low silver content, the nanobiomaterial showed a strong catalytic efficacy in different model reactions. Then, its virucidal activity was evaluated under different conditions. At 200 ppm, in combination with hydrogen peroxide, it inactivated 99% of human rhinovirus B14 and 99.99% of human coronavirus 229E. At 1000 ppm, it achieved 90% efficacy against MPXV and a 4.8 log
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.